GDC-0834 is a small molecule inhibitor primarily known for its role in targeting the enzyme phosphoinositide 3-kinase (PI3K), specifically the delta isoform (PI3Kδ). This compound has garnered attention in the field of oncology and immunology due to its potential therapeutic applications in treating various cancers and autoimmune diseases. GDC-0834 exhibits selective inhibition, which is crucial for minimizing off-target effects and enhancing therapeutic efficacy. The substance is characterized by its ability to modulate cellular signaling pathways, thereby influencing cell proliferation, survival, and immune responses. In preclinical studies, GDC-0834 has demonstrated promising results in reducing tumor growth and improving immune function. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are essential for determining its suitability for clinical use. As research continues, GDC-0834 may contribute to the development of targeted therapies that leverage its specific action on PI3Kδ, offering new avenues for treatment in relevant disease contexts.

GDC-0834

1133432-46-8: GDC-0834 is a small molecule inhibitor primarily known for its role in targeting the enzyme phosphoinositide 3-kinase (PI3K), specifically the delta isoform (PI3Kδ). This compound has garnered attention in the field of oncology and immunology due to its potential therapeutic applications in treating various cancers and autoimmune diseases. GDC-0834 exhibits selective inhibition, which is crucial for minimizing off-target effects and enhancing therapeutic efficacy. The substance is characterized by its ability to modulate cellular signaling pathways, thereby influencing cell proliferation, survival, and immune responses. In preclinical studies, GDC-0834 has demonstrated promising results in reducing tumor growth and improving immune function. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are essential for determining its suitability for clinical use. As research continues, GDC-0834 may contribute to the development of targeted therapies that leverage its specific action on PI3Kδ, offering new avenues for treatment in relevant disease contexts.

<p>GDC-0834 is a new investigational drug that has been shown in animal studies to have anti-leukemic activity. GDC-0834 is an orally active, potent inhibitor of the enzyme aminopeptidase N (APN). It was found to be effective in inhibiting the growth of human leukemia cells in vitro and in vivo, and to reduce the number of circulating leukemic cells in humans with chronic lymphocytic leukemia. The mechanism by which GDC-0834 inhibits APN is not understood, but it may involve a nucleophilic attack on the amide group of the enzyme.</p>

GDC-0834 Racemate

GDC-0834 Racemate is the racemate form of GDC-0834, which is an effective and selective BTK inhibitor

CAS 1133432-46-8

GDC-0834

GDC-0834 Racemate

Ref: 3D-IVB43246

GDC-0834 Racemate

Ref: TM-T11378L